Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Paul_Wotton
|
| gptkbp:collaboratesWith |
gptkb:Bristol_Myers_Squibb
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
precision medicine
synthetic biology cell and gene therapy |
| gptkbp:foundedYear |
2015
|
| gptkbp:founder |
gptkb:Michael_Gilman
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Obsidian Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:investor |
gptkb:RA_Capital_Management
gptkb:Atlas_Venture gptkb:Amgen_Ventures gptkb:Novo_Holdings GV (formerly Google Ventures) |
| gptkbp:notableProduct |
gptkb:CytoDRIVE_platform
|
| gptkbp:platform |
gptkb:proteolysis-targeting_chimera_(PROTAC)
|
| gptkbp:specializesIn |
controllable cell therapies
|
| gptkbp:website |
https://obsidiantx.com/
|
| gptkbp:bfsParent |
gptkb:Mark_Leschly
|
| gptkbp:bfsLayer |
6
|